Literature DB >> 7452216

Disability and intellectual function in multiple sclerosis patients.

G G Marsh.   

Abstract

Forty-eight multiple sclerosis patients were rated on the Kurtzke Disability Status Examination and tested on the Wechsler Adult Intelligence Scale. Their disability status scores, ranging from 1 to 9, with a mean of 3.98, correlated significantly only with duration of illness (r = .33, significant at the.05 level). Severity of disability was not significantly correlated with age of patient, age at onset of multiple sclerosis symptoms, Verbal IQ, Performance IQ, or Full Scale IQ. Wechsler Adult Intelligence Scale mean subtest scores ranged from average to bright normal. Scores on Performance subtests with a large motor component were lower than on Verbal subtests measuring verbal overlearned information, abstract reasoning, and vocabulary.

Entities:  

Mesh:

Year:  1980        PMID: 7452216     DOI: 10.1097/00005053-198012000-00009

Source DB:  PubMed          Journal:  J Nerv Ment Dis        ISSN: 0022-3018            Impact factor:   2.254


  4 in total

1.  Studies on regional cerebral oxygen utilisation and cognitive function in multiple sclerosis.

Authors:  D J Brooks; K L Leenders; G Head; J Marshall; N J Legg; T Jones
Journal:  J Neurol Neurosurg Psychiatry       Date:  1984-11       Impact factor: 10.154

2.  Deficient learning and memory in early and middle phases of multiple sclerosis.

Authors:  I Grant; W I McDonald; M R Trimble; E Smith; R Reed
Journal:  J Neurol Neurosurg Psychiatry       Date:  1984-03       Impact factor: 10.154

3.  Decline of cognition in multiple sclerosis: dissociable deficits.

Authors:  A Jennekens-Schinkel; E A Sanders
Journal:  J Neurol Neurosurg Psychiatry       Date:  1986-12       Impact factor: 10.154

4.  Clinically isolated lesions of the type seen in multiple sclerosis: a cognitive, psychiatric, and MRI follow up study.

Authors:  A Feinstein; L D Kartsounis; D H Miller; B D Youl; M A Ron
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-10       Impact factor: 10.154

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.